Table 1. Characteristics and responses... | American Society of Hematology

Table 1.

Characteristics and responses of T-PLL patients treated with CAMPATH-1H

Patient	Age^*/ sex	Prior therapy	Best response to prior therapy	Site of disease^*	WCC^* (× 10⁹/L)	Total dose CAMPATH	Response to CAMPATH	Duration of response	Immuno-phenotype (CD)^†	Status, cause of death	Survival from CAMPATH
1	49/F	VAPEC-B, Sx, DCF	PR	1. B/BM	1. 24	1. 530 mg	1. CR	1. 30 mo	4⁺/8⁺	Dead, infection	54 mo
				2. B/BM	2. 20.2	2. 670 mg	2. CR	2. 16 mo
2	53/M	DCF	PR	1. B/BM	1. 8	1. 660 mg	1. CR	1. 21 mo	4⁺/8⁺	Dead, PD	52 mo
				2. B/BM	2. 14.3	2. 170 mg	2. CR	2. 6 mo
3	61/M	DCF	NR	1. B/BM	1. 715	1. 890 mg	1. CR	1. 5 mo	4⁺/8⁺	Dead, PD	17 mo
		CHOP		2. B/BM	2. 105	2. 1325 mg	2. CR	2. 5 mo
4	77/M	DCF	NR	1. B/BM/Sp/H	1. 148.8	1. 388 mg	1. CR	6 mo	4⁺/8⁻	Dead, infection	8 mo
				2. B/BM/Sp/H	2. 16	2. 153 mg	2. CR	2. N/E
5	43/M	DCF	PR	1. Residual BM	Normal	1. 180 mg	1. CR	23+ mo	4⁺/8⁺	Alive	24+ mo
				2. Molecular relapse		2. 180 mg	2. CR
6	63/F	DCF	NR	1. B/BM/Sp/H/S	201	1. 803 mg	1. CR	10 mo	4⁺/8⁻	Dead, PD in CNS	16 mo
				2. C/B/S		2. 263 mg	2. PR
7	51/F	Prednisolone	NR	1. B/BM/S	1. 117	1. 436 mg	1. CR	7 mo	4⁺/8⁻	Dead, PD	9 mo
				2. B/BM/S		2. 450 mg	2. PD
8	63/M	DCF	PR	1. B/BM/Sp/LN	1. 94.0	1. 665 mg	1. CR	6 mo	4⁺/8⁻	Dead, PD	8 mo
				2. B/BM/Sp/LN	2. 34.5	2. 40 mg	2. PD
9	58/F	C + P, leukapheresis	NR	1. B/BM/Sp/LN	1. 456	1. 820 mg	1. CR	5 mo	4⁺/8⁻	Dead, PD	9 mo
				2. B/BM	2. 38.4	2. 390 mg	2. N/E
10	62/M	Chlor, DCF, Sx, CNOP	NR	B/BM	95.6	1. 320 mg	1. CR	45 mo	4⁻/8⁺	Dead, PD	46 mo
				B/BM/H/LN	35.0	2. 70 mg	2. NR
11	47/F	NONE		B/BM	1. 111	1. 900 mg	1. CR	25 mo	4⁻/8⁺	Dead, PD	27 mo
					2. 140	2. 800 mg	2. NR
12	46/M	DCF, ALL-like CT	PR	1. B/BM	178	1. 883 mg	1. CR	4 mo	4⁺/8⁺	Dead, PD	14 mo
				2. B/BM		2. 300 mg	2. NR
13	68/F	DCF	NR	B/BM/Sp	76	800 mg	CR	8 mo	4⁺/8⁻	Dead, thrombosis	9 mo
14	59/M	DCF	PR	B/BM/LN	4.8	333 mg	CR	8 mo	4⁺/8⁻	Dead, ALS	15 mo
15	74/M	DCF	NR	B/BM/Sp/H/LN	323.4	388 mg	CR	9 mo	4⁺/8⁻	Alive	23+ mo
16	63/M	DCF	NR	B/BM/Sp	318	540 mg	CR	6+ mo		Alive	16+ mo
17	57/M	DCF	PR	Residual BM	6.4	466 mg	CR	N/E	4⁺/8⁺	Dead, TRM	2 mo
18	44/M	Steroids, methotrexate, Sx, 2CDA	PR	B/BM	139	463 mg	CR	19 mo	4⁻/8⁺	Alive	22+ mo
19	58/F	CHOP	NR	B/BM, LN, C	115	1002 mg	CR	7+ mo	4⁺/8⁻	Alive	10+ mo
20	60/F	NONE		B/BM/LN/Sp	315	493 mg	CR	5+ mo	4⁺/8⁻	Alive	6+ mo
21	40/M	DCF, Sx	NR	B/BM	36.5	423 mg	CR	4 mo	4⁻/8⁺	Alive	29+ mo
22	38/M	DCF, CHOP	NR	B/BM/Lung	34	540 mg	CR	9 mo	4⁺/8⁻	Dead, PD	23 mo
23	75/M	Chlorambucil	NR	B/BM	484	483 mg	CR	9 mo	4⁻/8⁺	Dead, Ca stomach	9 mo
24	78/M	DCF	PR	1. B/BM/Sp	1. 4.0	1. 230 mg	1. PR	5 mo	4⁻/8⁺	Dead, PD	8 mo
				2. B/BM	2. 219	2. 50 mg	2. PD
25	60/M	CHOP	NR	B/BM/Sp/LN/H	102.8	470 mg	PR^‡	N/E^1-153	4⁺/8⁺	Dead, infection	2 mo
		DCF
26	67/M	DCF	PR	B/BM/Brain	130	635 mg	PR	1 mo	4⁺/8⁺	Dead, PD	4 mo
27	59/F	COP, DCF	NR	B/BM/Sp	140	633 mg	PR	7 mo	4⁺/8⁺	Dead, PD	10 mo
28	51/M	DCF	NR	B/BM/S	88	1093 mg	PR		4⁻/8⁺	Alive	12+ mo
29	56/M	CHOP, DCF	NR	B/BM/Sp/LN	400	630 mg	PR	4 mo	4⁺/8⁺	Dead, PD	12 mo
30	57/M	Steroids, DCF	PR	B/BM/C	97.1	450 mg	NR^1-155	—	4⁺/8⁺	Dead, PD	5 mo
31	45/M	C + P, CHOP, DCF	NR	B/BM/Sp/LN/H	660	630 mg	NR	—	4⁺/8⁺	Dead, PD	5 wk
32	38/M	DCF, Sx, various	PR	B/BM/S/C/H/A	86	200 mg	NR	—	4⁺/8⁺	Dead, PD	3 wk
33	62/F	DCF	PR	B/BM/Sp/LN/H/P	68.6	70 mg	NR	—	4⁺/8⁻	Dead, PD	1 wk
34	M	DCF	NR	BM/LN/Sp		133 mg	NR	—	4⁻/8⁺	Dead, PD	6 mo
35	67/F	2CDA, FDR	MR	B/BM/S	74.8	500 mg	NR	—	4⁺/8⁺	Dead, PD	5 mo
36	52/M	DCF	NR	B/BM/Sp/H/LN/S	42.1	1163 mg	NR	—	4⁺/8⁺	Dead, PD	8 mo
37	50/M	DCF	NR	B/BM/Sp/H/LN	14	180 mg	NR	—	4⁻/8⁺	Alive	18+ mo
38	34/M	COP, Sx, DCF	MR	BM/H/P/A	230	283 mg	NR	—	4⁺/8⁺	Dead, PD	3 wk
39	45/M	CHOP, FDR, ESHAP	NR	B/BM/Sp/H	50	213 mg	NE	—	4⁺/8⁻	Dead, unknown	2 wk

Patient	Age^*/ sex	Prior therapy	Best response to prior therapy	Site of disease^*	WCC^* (× 10⁹/L)	Total dose CAMPATH	Response to CAMPATH	Duration of response	Immuno-phenotype (CD)^†	Status, cause of death	Survival from CAMPATH
1	49/F	VAPEC-B, Sx, DCF	PR	1. B/BM	1. 24	1. 530 mg	1. CR	1. 30 mo	4⁺/8⁺	Dead, infection	54 mo
				2. B/BM	2. 20.2	2. 670 mg	2. CR	2. 16 mo
2	53/M	DCF	PR	1. B/BM	1. 8	1. 660 mg	1. CR	1. 21 mo	4⁺/8⁺	Dead, PD	52 mo
				2. B/BM	2. 14.3	2. 170 mg	2. CR	2. 6 mo
3	61/M	DCF	NR	1. B/BM	1. 715	1. 890 mg	1. CR	1. 5 mo	4⁺/8⁺	Dead, PD	17 mo
		CHOP		2. B/BM	2. 105	2. 1325 mg	2. CR	2. 5 mo
4	77/M	DCF	NR	1. B/BM/Sp/H	1. 148.8	1. 388 mg	1. CR	6 mo	4⁺/8⁻	Dead, infection	8 mo
				2. B/BM/Sp/H	2. 16	2. 153 mg	2. CR	2. N/E
5	43/M	DCF	PR	1. Residual BM	Normal	1. 180 mg	1. CR	23+ mo	4⁺/8⁺	Alive	24+ mo
				2. Molecular relapse		2. 180 mg	2. CR
6	63/F	DCF	NR	1. B/BM/Sp/H/S	201	1. 803 mg	1. CR	10 mo	4⁺/8⁻	Dead, PD in CNS	16 mo
				2. C/B/S		2. 263 mg	2. PR
7	51/F	Prednisolone	NR	1. B/BM/S	1. 117	1. 436 mg	1. CR	7 mo	4⁺/8⁻	Dead, PD	9 mo
				2. B/BM/S		2. 450 mg	2. PD
8	63/M	DCF	PR	1. B/BM/Sp/LN	1. 94.0	1. 665 mg	1. CR	6 mo	4⁺/8⁻	Dead, PD	8 mo
				2. B/BM/Sp/LN	2. 34.5	2. 40 mg	2. PD
9	58/F	C + P, leukapheresis	NR	1. B/BM/Sp/LN	1. 456	1. 820 mg	1. CR	5 mo	4⁺/8⁻	Dead, PD	9 mo
				2. B/BM	2. 38.4	2. 390 mg	2. N/E
10	62/M	Chlor, DCF, Sx, CNOP	NR	B/BM	95.6	1. 320 mg	1. CR	45 mo	4⁻/8⁺	Dead, PD	46 mo
				B/BM/H/LN	35.0	2. 70 mg	2. NR
11	47/F	NONE		B/BM	1. 111	1. 900 mg	1. CR	25 mo	4⁻/8⁺	Dead, PD	27 mo
					2. 140	2. 800 mg	2. NR
12	46/M	DCF, ALL-like CT	PR	1. B/BM	178	1. 883 mg	1. CR	4 mo	4⁺/8⁺	Dead, PD	14 mo
				2. B/BM		2. 300 mg	2. NR
13	68/F	DCF	NR	B/BM/Sp	76	800 mg	CR	8 mo	4⁺/8⁻	Dead, thrombosis	9 mo
14	59/M	DCF	PR	B/BM/LN	4.8	333 mg	CR	8 mo	4⁺/8⁻	Dead, ALS	15 mo
15	74/M	DCF	NR	B/BM/Sp/H/LN	323.4	388 mg	CR	9 mo	4⁺/8⁻	Alive	23+ mo
16	63/M	DCF	NR	B/BM/Sp	318	540 mg	CR	6+ mo		Alive	16+ mo
17	57/M	DCF	PR	Residual BM	6.4	466 mg	CR	N/E	4⁺/8⁺	Dead, TRM	2 mo
18	44/M	Steroids, methotrexate, Sx, 2CDA	PR	B/BM	139	463 mg	CR	19 mo	4⁻/8⁺	Alive	22+ mo
19	58/F	CHOP	NR	B/BM, LN, C	115	1002 mg	CR	7+ mo	4⁺/8⁻	Alive	10+ mo
20	60/F	NONE		B/BM/LN/Sp	315	493 mg	CR	5+ mo	4⁺/8⁻	Alive	6+ mo
21	40/M	DCF, Sx	NR	B/BM	36.5	423 mg	CR	4 mo	4⁻/8⁺	Alive	29+ mo
22	38/M	DCF, CHOP	NR	B/BM/Lung	34	540 mg	CR	9 mo	4⁺/8⁻	Dead, PD	23 mo
23	75/M	Chlorambucil	NR	B/BM	484	483 mg	CR	9 mo	4⁻/8⁺	Dead, Ca stomach	9 mo
24	78/M	DCF	PR	1. B/BM/Sp	1. 4.0	1. 230 mg	1. PR	5 mo	4⁻/8⁺	Dead, PD	8 mo
				2. B/BM	2. 219	2. 50 mg	2. PD
25	60/M	CHOP	NR	B/BM/Sp/LN/H	102.8	470 mg	PR^‡	N/E^1-153	4⁺/8⁺	Dead, infection	2 mo
		DCF
26	67/M	DCF	PR	B/BM/Brain	130	635 mg	PR	1 mo	4⁺/8⁺	Dead, PD	4 mo
27	59/F	COP, DCF	NR	B/BM/Sp	140	633 mg	PR	7 mo	4⁺/8⁺	Dead, PD	10 mo
28	51/M	DCF	NR	B/BM/S	88	1093 mg	PR		4⁻/8⁺	Alive	12+ mo
29	56/M	CHOP, DCF	NR	B/BM/Sp/LN	400	630 mg	PR	4 mo	4⁺/8⁺	Dead, PD	12 mo
30	57/M	Steroids, DCF	PR	B/BM/C	97.1	450 mg	NR^1-155	—	4⁺/8⁺	Dead, PD	5 mo
31	45/M	C + P, CHOP, DCF	NR	B/BM/Sp/LN/H	660	630 mg	NR	—	4⁺/8⁺	Dead, PD	5 wk
32	38/M	DCF, Sx, various	PR	B/BM/S/C/H/A	86	200 mg	NR	—	4⁺/8⁺	Dead, PD	3 wk
33	62/F	DCF	PR	B/BM/Sp/LN/H/P	68.6	70 mg	NR	—	4⁺/8⁻	Dead, PD	1 wk
34	M	DCF	NR	BM/LN/Sp		133 mg	NR	—	4⁻/8⁺	Dead, PD	6 mo
35	67/F	2CDA, FDR	MR	B/BM/S	74.8	500 mg	NR	—	4⁺/8⁺	Dead, PD	5 mo
36	52/M	DCF	NR	B/BM/Sp/H/LN/S	42.1	1163 mg	NR	—	4⁺/8⁺	Dead, PD	8 mo
37	50/M	DCF	NR	B/BM/Sp/H/LN	14	180 mg	NR	—	4⁻/8⁺	Alive	18+ mo
38	34/M	COP, Sx, DCF	MR	BM/H/P/A	230	283 mg	NR	—	4⁺/8⁺	Dead, PD	3 wk
39	45/M	CHOP, FDR, ESHAP	NR	B/BM/Sp/H	50	213 mg	NE	—	4⁺/8⁻	Dead, unknown	2 wk

Patients 1-12 were treated twice; numbers 1 and 2 refer to first and second courses of CAMPATH-1H treatment.

For the duration of response, 3+ months denotes continuing CR at 3 months.

Sx indicates splenectomy; DCF, deoxycoformycin; B, blood; PD, progressive disease; Sp, spleen; H, liver; S, skin; C, central nervous system; LN, lymph nodes; N/E, nonevaluable; Chlor, chlorambucil; CNOP, cyclophosphamide, vincristine, prednisone, mitoxantrone; ALL-like CT, acute lymphoblastic leukemia–type chemotherapy regimen; ALS, amyotrophic lateral sclerosis; TRM, transplant-related mortality; 2CDA, cladrabine; C + P, chlorambucil and prednisolone; A, ascites; P, pleural effusion; FDR, fludarabine; ESHAP, methylprednisolone, etoposide, cytarabine, cisplatin.

At the time of CAMPATH-1H treatment.

†

All patients were CD2⁺, CD7⁺, CD3⁺, the table indicates phenotype with respect to CD4 and CD8 antigens.

‡

Clearance of peripheral blood, Sp, S, and LN but BM hypoplasia and residual T-PLL.

F1-153

Died of aplasia while in PR.

F1-155

Peripheral blood and BM cleared but prolymphocytes reappeared here within 4 weeks.

View Large

This Feature Is Available To Subscribers Only